TP53 and cancer: Betulinic acid exerted its anti-proliferative activity on all the tested lines in a very narrow range of doses (1.5 - 4.5 mg/mL), and was effective against wild-type p53 and mutant p53 neoplastic cell lines derived from cancers clinically resistant to conventional anti-neoplastic drugs.